Entecavir monohydrate

Entecavir monohydrate (BMS200475 monohydrate; SQ34676 monohydrate) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.

Product information

CAS Number: 209216-23-9

Molecular Weight: 295.29

Formula: C12H17N5O4

Synonym:

BMS200475 monohydrate

SQ34676 monohydrate

Entecavir hydrate

Related CAS Number:

142217-69-4 (Entecavir anhydrous)

188399-46-4 (ent-Entecavir)

911138-73-3 (Entecavir maleate)

Chemical Name: 2-amino-9-[(1S, 3R, 4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6, 9-dihydro-1H-purin-6-one hydrate

Smiles: O.C=C1[C@H](CO)[C@@H](O)C[C@@H]1N1C=NC2C(=O)NC(N)=NC1=2

InChiKey: YXPVEXCTPGULBZ-WQYNNSOESA-N

InChi: InChI=1S/C12H15N5O3.H2O/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20;/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20);1H2/t6-,7-,8-;/m0./s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 59 mg/mL(199.8 mM). Water: Insoluble.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Entecavir-triphosphate is a highly potent inhibitor of wild-type HBV Pol and is 100- to 300-fold more potent than lamivudine-triphosphate against 3TC-resistant HBV Pol. Entecavir inhibits the replication of 3TC-resistant HBV, but 20- to 30-fold higher concentrations are required. Entecavir results in an impressive reduction of serum viral DNA with covalently closed circular DNA and hepatitis B viral core antigen negativity in liver biopsy specimens. Entecavir has potent activity (EC50, 0.1 nM) against HIV in a unique single-cycle, single-cell-based pseudovirus assay (24) with CD4+ lymphocytes using a green fluorescent protein reporter fluorescence-activated cell sorter assay as the endpoint.

In Vivo:

Entecavir causes a 4-log drop in serum DHBV DNA levels within 80 days and a slower 2- to 3-log drop in serum DHBV surface antigen (DHBsAg) levels within 120 days in ducks. Entecavir treatment reduces DHBV DNA replicative intermediates 70-fold in the liver, while the level of the stable, template form, covalently closed circular DNA decreases only 4-fold in ducks. Entecavir treatment reduces both the intensity of antigen staining and the percentage of antigen-positive hepatocytes in the liver, but the intensity of antigen staining in bile duct cells appeares not to be effected in ducks.

References:

1. Lin PF, et al. Antimicrob Agents Chemother, 2008, 52(5), 1759-1767.
2. Honkoop P1, et al. Expert Opin Investig Drugs, 2003, 12(4), 683-688.
3. Levine S, et al. Antimicrob Agents Chemother, 2002, 46(8), 2525-2532.

Products are for research use only. Not for human use.